Pulmo BioTech Inc. Announces Attendance At RSNA 2010

NEW YORK, July 6, 2010 (GLOBE NEWSWIRE) -- Pulmo BioTech Inc. (OTCBB:PLMO) (Frankfurt:PB0) announces that later this year it intends to exhibit at RSNA 2010, the 96th Scientific Assembly & Annual Meeting of the Radiological Society of North America, which hosts nearly 60,000 attendees from around the world. "With the company expecting to complete Phase I Clinical Trials this year, now is the time for us to start to increase our exposure to the wider medical community in conjunction with our policy of publishing technical papers. It is now appropriate that Pulmo Biotech should be in attendance at this conference." – Garry McCann, CEO Pulmo BioTech Inc.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. (OTCBB:PLMO) (Frankfurt:PB0) specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stockholders.

ISIN: US7458451074

CUSIP: 745845107

WKN: A0RDTZ

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind ^TM.

PulmoScience was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn Dupuis (the scientific director and originator of the PulmoBind ^TM Molecular Imaging technology), and by Pulmo BioTech Inc. as the funding partner, PulmoScience Inc. aims to develop this unique and exciting technology, to fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth in excess of $500 million per annum and that, provided Regulatory Approval is achieved, the safety and efficacy of its products could allow it to dominate that market.